https://doctransparency.com/doctor/tx/frisco/jared-lee-1972949352
Medicare Enrolled

Dr. Jared Lee, M.D.

Pulmonary Disease · Frisco, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
16050 EVERWELL LN STE 400, Frisco, TX 75033
9728174200
In practice since 2013 (12 years)
NPI: 1972949352 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Lee from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lee? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Lee

Dr. Jared Lee is a pulmonary disease in Frisco, TX, with 12 years in practice. Based on federal Medicare data, Dr. Lee performed 3,354 Medicare services across 1,688 unique beneficiaries.

Between the years covered by Open Payments, Dr. Lee received a total of $7,235 from 25 pharmaceutical and/or device companies across 87 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Lee is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 12 years in practice▲ Top 8% volume in TX$ $7,235 industry payments

Medicare Practice Summary

Medicare Utilization ↗
3,354
Medicare services
Top 8% in TX for pulmonary disease
1,688
Unique beneficiaries
$99
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~280 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Hospital follow-up visit, high complexity1,029$95$262
Critical care, first 30-74 min532$172$573
Hospital follow-up visit, moderate complexity220$63$183
Office visit, established patient (30-39 min)213$97$333
Office visit, established patient, complex (40-54 min)190$141$469
Test to determine lung volumes using sensors129$43$143
Test to measure expiratory airflow and volume128$21$70
Test to examine how well the lungs exchange gases128$45$154
Initial hospital admission, high complexity110$139$508
Blood count, hemoglobin96$2$6
Chest X-ray, 2 views95$19$89
Steroid injection (triamcinolone)90$1$31
Drainage of fluid from chest cavity with insertion of indwelling tube using imaging guidance42$540$1,823
Test to measure expiratory airflow and volume changes before and after medication administration42$31$102
New patient office visit (45-59 min)42$128$434
Ultrasound scan of chest37$35$126
Irrigation and suction of lung airways to obtain cells using an endoscope31$30$682
Aspiration of initial secretion of lung airway using an endoscope29$64$728
New patient office visit, complex (60-74 min)27$174$574
Destruction of growth or narrowing of lung airway using an endoscope21$195$660
Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes18$10$32
Test for exercise-induced lung stress16$27$87
Initial hospital admission, moderate complexity16$101$346
Needle biopsy of windpipe cartilage, airway, and/or lung using an endoscope13$67$1,233
Computer-assisted image-guided navigation of lung airways using an endoscope12$77$3,056
Biopsy of lobe of lung using an endoscope, 1 lobe12$35$1,005
Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes12$103$3,513
Exam of lung airways with diagnostic or therapeutic procedure on growths using an endoscope and ultrasound12$53$322
Drug injection, under skin or into muscle12$11$43
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$7,235
Total received (2018-2024)
Avg $1,206/year across 6 years
Top 26% in TX for pulmonary disease
25
Companies
87
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,525 (62.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,710 (37.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$301
2023
$1,833
2021
$3,536
2020
$271
2019
$705
2018
$589

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Intuitive Surgical, Inc.
$4,525
Ethicon Inc.
$511
Astellas Pharma US Inc
$317
Actelion Pharmaceuticals US, Inc.
$293
Pulmonx Corporation
$267
GlaxoSmithKline, LLC.
$201
Boehringer Ingelheim Pharmaceuticals, Inc.
$198
Bayer HealthCare Pharmaceuticals Inc.
$158
Allergan Inc.
$131
Genentech USA, Inc.
$115
BOSTON SCIENTIFIC CORPORATION
$76
Sandoz Inc.
$51
Merck Sharp & Dohme Corporation
$47
Olympus America Inc.
$45
GENZYME CORPORATION
$42
Mylan Specialty L.P.
$40
Olympus Corporation of the Americas
$40
PFIZER INC.
$35
AstraZeneca Pharmaceuticals LP
$27
Advanced Respiratory, Inc
$24
Grifols USA, LLC
$21
PORTOLA PHARMACEUTICALS, LLC
$21
ABBVIE INC.
$18
Gilead Sciences, Inc.
$17
ADVANCED RESPIRATORY, INC
$14
Top 3 companies account for 74.0% of total payments
Associated products mentioned in payments ›
ANDEXXA · AREXVY · AVYCAZ · Adempas · CHANTIX · CHARTIS CATHETER · CRESEMBA · DA VINCI SP · DALVANCE · DUPIXENT · Da Vinci Surgical System · FASENRA · Monarch Platform · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · Olympus Bronchoscopes · Pulmonx Endobronchial Valve EBV · Spiration Valve System · TEZSPIRE · TRELEGY ELLIPTA · TREPROSTINIL · The Vest System Model 105 Home Care · UPTRAVI · WALLFLEX · Xembify · Yupelri · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (62%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in pulmonary disease and does not inherently indicate bias, but patients may wish to be aware.

Equivalent to $216 per 100 Medicare services performed
Looking for a pulmonary disease in Frisco?
Compare pulmonary diseases in the Frisco area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary Diseases within 10 mi
65
Per 100K population
6.9
County median income
$108,185
Nearest hospital
TEXAS HEALTH HOSPITAL FRISCO
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Lee is a mixed practice specialist, with above-average Medicare volume (top 8% in TX), and speaking/promotional industry engagement.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Lee experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Lee performed 1,029 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lee receive payments from pharmaceutical companies?
Yes. Dr. Lee received a total of $7,235 from 25 companies across 87 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lee's costs compare to other pulmonary diseases in Frisco?
Dr. Lee's average Medicare payment per service is $99. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lee) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →